Ovarian Cancer Research Alliance Community Partner

RSS News

  • 3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients July 7, 2020
    An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D) […]
  • Second Surgery May Aid Survival in Recurrent Ovarian Cancer, Study Finds June 30, 2020
    Woman whose ovarian cancer returns more than six months after initial surgery and chemotherapy may benefit from a second surgery, but only if the entire tumor is removed during the procedure, data from a clinical trial show. Patients should be carefully selected for a second surgery, based on the likelihood that this surgery will successfully remove […]
  • Groups Pledge Funding for Project to Develop Ovarian Cancer Blood Test June 25, 2020
    A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The Bourne Foundation, as well as a further funding pledge from Tour de Cure, to advance research into the development of blood tests for the early diagnosis of ovarian cancer. “Despite decades of research, there is currently no easily accessible, non-invasive and […]
  • Protein Biomarkers to Gauge Cancer Response to Chemo Identified June 23, 2020
    Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ovarian cancer found a wide variety of biomarkers that might help predict which chemotherapies patients are more likely to respond to, the precision medicines company mProbe reported. Identifying these tumor biomarkers is crucial not only to spotting potential targets for future therapies, but also […]
  • Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses June 18, 2020
    When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate receptor alpha (FRα), top-line data from a Phase 1b/2 trial shows. The trial findings were presented in “Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug […]
  • DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show June 16, 2020
    A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated findings from a Phase 1/2 clinical trial show. “We believe these results highlight DPX-Survivac’s potential to alter the treatment landscape in advanced ovarian cancer and […]
  • Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds June 11, 2020
    A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the time without disease progression in people with platinum-sensitive relapsed ovarian cancer, findings from a clinical trial show. The combination also delayed the need for subsequent treatment by prolonging time without disease worsening, and showed a trend toward better survival rates, […]
  • More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows June 9, 2020
    VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 trial responding to a combination treatment. Since the OVAL trial (NCT03398655) has met pre-specified criteria, as an interim analysis found, an independent data safety monitoring […]
  • Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home June 4, 2020
    Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely in the safety of the patients’ homes, according to data from an early Phase 1 trial. The trial findings also showed that genetic counseling sessions performed before and after testing can be skipped entirely without causing additional distress to patients. […]
  • Breastfeeding Lowers Risk of Ovarian Cancer for Decades, Study Finds June 2, 2020
    Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and some of its subtypes, including the deadliest — high-grade serous tumors, a large data study reported. This finding was particular to white women — because not enough black and Asian women could be included in the analysis — strengthened with longer […]
  • Phase 2 Trial to Test Exercise as Way to Improve Quality of Life in Recurring Ovarian Cancer May 27, 2020
    A new Phase 2 clinical trial in Australia will assess whether exercise can improve the quality of life and physical function of women with recurring ovarian cancer who are on chemotherapy. Researchers at Griffith University recently were awarded a AU$884,172 grant (about $581,000) from the Medical Research Future Fund for this project. They will collaborate with teams at […]
  • SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer May 20, 2020
    Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women with BRCA-mutated relapsed ovarian cancer, whose tumors responded to platinum-based chemotherapy, final results from the SOLO-2 Phase 3 clinical trial show. Trial findings, “Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) […]
  • Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial May 13, 2020
    Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy plus Avastin, interim results from a Phase 2 trial show. These findings are in the presentation, “Phase II OVARIO study of niraparib + bevacizumab therapy […]
  • FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer May 12, 2020
    The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients who have advanced fallopian tube or primary peritoneal cancer. HRD-positive tumors — present in one of every two women with advanced ovarian […]
  • STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show May 6, 2020
    STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR) […]